HistoSonics has closed on a $250 million financing round led by the company's new ownership group and additional investors Thiel Bio and Founders Fund, among others.
The financing will support the ongoing commercial expansion of HistoSonics’ Edison System into new global markets, speed new clinical indications, and strengthen operational capacity for the next phase of growth, it said.
This funding follows the recent $2.25 billion majority stake acquisition of HistoSonics by a consortium of international technology and life science investors, including K5 Global, Bezos Expeditions, and Wellington Management -- all of which participated in the new round as well.
HistoSonics plans to expand beyond its initial focus on liver tumors to kidney, pancreas, and prostate indications. The company seeks to establish histotripsy as a treatment option across clinical applications throughout the body, treating both benign and malignant conditions.
